Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 382

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 382
---
 summarized in this discussion

Executive Compensation Overview 

Our named executive officers (“NEOs”) for the year ended December 31, 2024, which consist of each person who served as our principal executive officer and the next two most highly-compensated executive officers who served during the year ended December 31, 2024, are as follows: 

•James Bianco, M.D., our President and Chief Executive Officer;

•Dan Dearborn, our Chief Financial Officer; 

•Robert Hoffman, our former President, Chief Executive Officer and Interim Chief Financial Officer; and

•Dennis Yamashita, Ph.D., our former Chief Scientific Officer

100

2024 Summary Compensation Table

The following table summarizes the compensation earned by, awarded to or paid to the NEOs for the years ended December 31, 2024 and 2023:

    Name and Principal Position

    Fiscalyear

    Salary ($)

    Bonus(1)

    StockAwards ($)

    OptionAwards(2)

    All OtherCompensation($)(3)

    Total ($)

    Dr. James Bianco

    2024

    463,734

    -

    -

    4,900,000

    80,000

    $
    5,443,734

    President and Chief Executive Officer

    2023

    439,834

    579,668

    -

    192,000

    83

    $
     
    1,211,585

    Dan Dearborn

    2024

    339,101

    -

    -

    2,200,000

    -

    $
    2,539,101

    Chief Financial Officer

    2023

    320,833

    254,326

    -

    42,240

    108

    $
     
    635,775

    Dennis Yamashita(4)

    2024

    320,833

    -

    -

    588,000

    -

    $
     
    908,833

    Former Chief Scientific Officer

    2023

    -

    -

    -

    -

    -

    $
     
    -

    Robert Hoffman(5)

    2024

    717,544

    397,669

    -

    -

    1,326,016(6)

    $
    2,441,229